

Original Article

Pachymic acid modified carbon nanoparticles reduced angiogenesis via inhibition of MMP-3

Jun Ma, Jun Liu, Chun-Wei Lu, Ding-Fang Cai

Department of Integrative Medicine, Zhongshan Hospital, Fudan University, Shanghai 200032, China

Received February 2, 2015; Accepted April 18, 2015; Epub May 1, 2015; Published May 15, 2015

Abstract: Angiogenesis is a process of new blood vessel generation, which is consistently and robustly correlated with tumor formation, growth, and metastasis. The disruption of angiogenesis, and the imbalanced endothelial remodeling and regression, are the main pathogenesis of malignant tumor. Recently, multi-walled nanotubes (MWNTs) have been proposed as a new tool for drug delivery in cancer treatment, which also displayed anti-angiogenic property. In the present study, we modified MWNTs with pachymic acid (PA) extracted from *Heterosmilax chinensis*, a traditional Chinese medicine used for cancer treatment, and compared their effects on blood vessel development. MWNTs and PA/MWNTs were evaluated for their influences on chorioallantoic membrane (CAM) vessel morphology and extracellular matrix metalloproteinase-3 (MMP-3) expression, a crucial proteinase associated with tumor metastasis. MWNTs functioned as an inhibitor of forming branch while PA was not able to promote this inhibition. Subsequently, MWNTs suppressed the endothelial cell maturation, accounting for the ceased elongation of CAM blood vessel, while PA/MWNTs increased the suppressive effect, indicating the potential roles of PA in preventing angiogenesis. PA/MWNTs also showed greater anti-angiogenic property as MMP-3 expression in CAM tissue was significantly decreased by PA/MWNTs compared to MWNTs. These results emphasize the anti-angiogenic activities of PA, supporting a new promising therapy for cancer from the perspective of traditional Chinese medicine.

Keywords: Angiogenesis, metalloproteinase-3, multi-walled nanotubes, metastasis

Introduction

Angiogenesis is a process of generating new blood vessels, which occurs as a consequence of sprouting new capillaries from preexisting vessels by assembling of endothelial cells, and vasculogenesis [1, 2]. It is based on the activation, migration, maturation, remodeling and regression of endothelial cells in normal circumstances. Endothelial cells can be stimulated by angiogenic stimuli to re-enter the cell cycle, degrade the underlying basement membrane to migrate, form new capillary sprouts, and then exit from the cell cycle to differentiate into new vessels [3, 4].

Tumor growth has been well documented to be accompanied by new blood vessel formation in order to acquire nutrients by enhancing the expression of cell growth factors and receptors such as vascular endothelial growth factor (VEGF), vascular endothelial growth factor receptor 2 (VEGFR-2) and fibroblast growth fac-

tor receptor (FGFR) [5-9]. Therefore, the disruption of angiogenesis, and the absence of endothelial remodeling and regression are the pivotal pathological features of malignant tumor. During sprouting angiogenesis, endothelial cells are able to sense the growth factors released from tumor cells in extracellular matrix (ECM), and then they produce proteases that degrade and remodel the ECM. This is in part achieved by the production of extracellular matrix metalloproteinase (MMPs), which cleaves the fibers of nearby ECM to alter the mechanical properties of ECM [10]. It was demonstrated that the overexpression of several types of MMPs was associated with the metastasis of tumor [11-13]. Potentially, the inhibition of MMPs activities can be a feasible and striking way to prevent tumor invasion by reducing angiogenesis hence blocking nutrient supply for tumor.

Over the last decade, VEGF inhibitors have emerged as a new anti-angiogenic cancer ther-

apy. However, anti-VEGF therapy is effective only in a limited number of cases and can lead to serious toxicity [14, 15]. In addition, inhibition of VEGF signaling pathway seems to be insufficient since angiogenesis involves a well-balanced crosstalk of hundreds of proteins. It has been documented that nanoparticles of diamond, graphite, graphene, nanotubes and fullerenes display low cytotoxicity and could serve as vehicle for drug delivery in cancer treatment [16, 17]. Interestingly these nanoparticles themselves also displayed anti-angiogenic properties [18]. In this study, we modified multi-walled nanotubes (MWNTs) with pachymic acid (PA) extracted from *Heterosmilax chinensis*, a traditional Chinese medicine used for cancer treatment, and observed improved effect on inhibition of angiogenesis.

Materials and methods

Pachymic acid separation

Extracts from *heterosmilax chinensis* were separated and analyzed by high performance liquid chromatography (HPLC) equipped with a Waters 1525 pump, a 2707 auto sampler and a 2998 PDA detector. The chromatographic separation was achieved at 30°C on Waters Sunfire™ C18 (250 mm × 4 mm i.d., 5 µm particle size) column. The run time was set at 35 min; the flow rate was 1.0 ml/min; and the sample injection volume was 10 µl. The mobile phase was 0.1% (v/v) phosphoric acid (A)-100% acetonitrile (B) filtered through a 0.45 µm filter and degassed prior to use. Separation was achieved with gradient elution using 0.1% phosphoric acid as a solvent. The gradient was reduced by 90% from 0 to 10 min, 75% from 10 to 20 min and 50% from 20 to 30 min, and was increased by 90% from 30 to 35 min to equilibrate the column. The flow rate was set at 1.0 ml/min and the samples were detected at 515 nm.

Modification of MWNTs

MWNTs were dispersed in distilled water and sonication was performed. Initially, MWNTs were incubated in a mixture of 20% (V/V) H₂SO₄ and 20% HNO₃ for 24 hours, followed by incubating in 10 mM PA and 20% H₂SO₄ for 24 hours at 37°C. After that, MWNTs were washed three times using distilled water and evaporated to dryness under a stream of warm air. Finally MWNTs/PA-MWNTs were re-dispersed in

PBS with sonication. Sonication was required for dispersing MWNTs/PA-MWNTs before each experiment. The shape and sized of MWNTs and PA-MWNTs were visualized using a JEM-2000EX transmission electron microscope (JEOL Ltd., Japan) at 200 kV.

Chorioallantoic membrane (CAM) assay

Chorioallantoic membrane (CAM) implants were made from sterile Waterman filter paper with a diameter of 5 mm. PBS (control), MWNTs or PA-MWNTs (500 mg/L) were respectively added to the implants (final amount of MWNTs on the implant was 0.01 mg). The implants were pre-treated with 3 mg/ml of hydrocortisone sodium succinate (Sigma, USA) and air dried under sterile conditions. Fertilized eggs from Ross line 308 hens were obtained from a certified hatchery and kept for 4 days at 12°C. The eggs were sterilized using UVC light. Embryos were incubated at temperature 37°C, humidity 60% and turned once per hour. Embryonic day 0 (E0) is the first day when the eggs were placed into the incubator. At day E6, small holes (1 cm²) were made on the shell above air space, the inner membrane was gently stripped off, and the implants were placed on CAM. The chicken embryos were incubated until day 7 of embryonic development, when implants with CAM were prefixed with 1.5 ml of 4% paraformaldehyde. After 30 min of incubation at 4°C, CAM with implants were cut out and fixed at 4°C in 4% paraformaldehyde for 60 min (total fixation time, 90 min). After fixation, the implants were gently stripped off.

CAM tissues from implants were investigated with a stereomicroscope under a 12.5-fold magnification (SZX10, Olympus Corporation, Japan). Photos were analyzed with ImageJ (NIH). The level of angiogenesis was determined by counting the branch (represents the vessel splitting process) and stop (represents the cell migration of endothelium) points in the area of direct contact of MWNTs or PA-MWNTs, usually with a diameter of 3 mm.

Western blot

The MMP-3 (~54 kDa) expressed in CAM tissue was determined by Western blot. 100 µl of each sample was harvested and added to 20 µl sample 2 × loading buffer (0.125 M of 5 M Tris-HCl, Amresco; 20% glycerol, USB; 4% of 10%




Figure 1. Modification of MWNTs with pachymic acid from *heterosmilax chinensis*. A. HPLC profile of *heterosmilax chinensis* and chemical structure of pachymic acid. B. Scanning electron microscopy of MWNTs and pachymic acid modified MWNTs (PA-MWNTs); scale bar, 100 nm.

sodium dodecyl sulfate, Amresco; 1% β -mercaptoethanol, Amresco; 0.2% of 0.05% (w/v) bromophenol blue, Sigma). Actin was used as a loading control. The samples were boiled for 5 min before loading. 10% running gel (25% of 40% acrylamide stock, Beyotime; 0.375 M of 1.5 M Tris-HCl, pH 8.8; 1% of 10% sodium dodecyl sulfate; 1% of 10% ammonium persulfate; 0.1% tetramethylethylenediamine) was utilized based on the range of molecular weights, which was from 15 to 100 kDa. After separation, proteins on the gel were transferred to a same size membrane (Nitrocellulose transfer membrane, Protian) within transfer buffer (25 mM Tris base, 192 mM Glycine, 0.037% sodium dodecyl sulfate, and 20% methanol) under 45 V for 40 min. The proteins that transferred onto the membrane were incubated with the primary antibody (ab52915 for MMP-3, Abcam; ab69512 for Actin as a loading control, Abcam) with a 1/1000 dilution in blocking buffer (50 mM Tris base; 100 mM NaCl; 0.02% Tween 20; and 3% BSA) overnight. The membrane was washed by TTBS (0.1% Tween 20, 10 mM Tris base, 100 mM NaCl, pH 7.5) for three times before adding secondary antibody (ab6721, Abcam) with 1/5000 dilution in blocking buffer for 2 hours. Background color was reduced by carefully washing with TTBS. The

results were visualized by developer and fixing solution

Statistical analysis

Data are presented as mean \pm SD. Comparisons between control, MWNT and PA-MWNT groups were made by a two-tailed Student's t test and $P < 0.05$ was considered as statistical significant. All data were computed using Excel Microsoft® Version 14.0.7128.5000 (© 2010 Microsoft Corporation, Santa Rosa, USA).

Results

Preparation of PA modified MWNTs

Purification of PA (Molecular weight: 528.76) from extracts of *Heterosmilax chinensis* was achieved by HPLC at 515 nm (Figure 1A). The shape and size

of MWNTs and PA modified MWNTs (PA-MWNTs) were observed by transmission electron microscopy (Figure 1B). Compared to MWNTs, PA-MWNTs are sparser and spreader, indicating the existence of PA between nanotubes.

PA-MWNT inhibited angiogenesis in CAM vessel assay

To investigate the impacts of PA on angiogenesis, we compared the development of blood vessels in embryo CAM between MWNTs and PA-MWNTs groups using CAM implantation method. Changes of CAM morphology by PA were observed (Figure 2A). Branch sprouting from the established blood vessels is an indicator of angiogenesis, and more branches indicate more dynamic activities of vessel development [19]. In control group (PBS-treated), the branch shown as red point was not affected, indicating angiogenesis was not affected. The branch and stop numbers in each group were all accounted (Figure 2B). Branch number was significantly decreased in MWNT group compare to PBS group ($P < 0.001$). PA did not have statistically significant impact on the reduction of branches. More stops were formed in the presence of MWNT ($P < 0.001$). Interestingly, PA




Figure 2. CAM vessel morphology in response to treatment with MWNTs and PA-MWNTs. A. Up, CAM vessel formation under microscope; down, schematic figures show the definition of “Branch” and “Stop” points. B. Summary of CAM essays; n=17 for each bar; ** and ***represents $P<0.01$ and 0.001 , respectively; †represents not significantly different.

modification also led to a significant increasing of stops ($P<0.01$), suggesting PA may decrease

vascular network via inhibiting the maturation but not migration of endothelial cells.




Figure 3. Western blot shows the inhibitory effect of MWNT and PA-MWNT on the expression of MMP-3. A. Representative gel graph of MMP-3 and β -actin under different treatment. B. Summary of Western blot; n=4 blots; ***represents $P<0.001$.

Stromelysin (MMP-3) expression affected by PA-MWNT

In order to know whether MWNT and PA-MWNT affect MMP-3 expression, western blot analysis was performed within control, MWNT and PA-MWNT groups respectively, with β -actin (~42 kDa) as loading control. As shown in **Figure 3A** and **3B**, MMP-3 expression was significantly down-regulated ($P<0.001$) by MWNT treatment, suggesting the inhibitory role of MWNT in MMP-3 expression. In comparison to MWNT group, PA-MWNT led to a substantially decreased ($P<0.001$) MMP-3 expression, supporting the potential roles of PA in inhibiting the MMP-3 expression.

Discussion

Previous studies showed striking evidence of the inhibition effects of MWNT on VEGF and fibroblast growth factor-2 (FGF2) induced angiogenesis [18]. In our study, MWNT slightly prevented angiogenesis, as indicated by the appearance of stops (blue point) in MWNT treated group (**Figure 2**). Whereas PA-MWNT exhibited significantly enhanced negative influences on angiogenesis, supported by more stops formed instead of branches. It suggests that PA plays a promising role in stop formation.

Endothelial cells can be stimulated by growth factors such as FGF-2 and VEGF. FGF-2 plays an essential role in inducing VEGF expression in forming blood vessels. VEGF, an angiogenic mitogen released from cells, is able to induce mitosis, differentiation, migration and survival of endothelial cells to form capillaries from primary vascular plexus and blood vessels during embryonic development or tumor growth [20-23]. The synergism between various growth factors and receptors maintains the balanced regulation of angiogenesis. MWNT and PA may also synergize as inhibitors of FGF-2 and VEGF. In order to obtain deeper insights of the influence of MWNT and PA on FGF-2 and VEGF, we measured the expression of MMP-3, a crucial protease in angiogenesis (**Figure 3**). MMP-3 is one of the most important metalloproteinases playing critical roles in degradation of extracellular matrix in tumor cell microenvironments, contributing in tumor invasion and angiogenesis [24-26]. As MMP-3 was predominantly associated with invasive carcinoma [27-29], the reduction of MMP-3 by PA-MWNT can be a remarkable step for treating cancer. The results in this study suggest the potential roles of PA in inhibiting the MMP-3 expression.

VEGF stimulates proteolytic activity of endothelial cells, and MMP-3 expression was shown to be regulated by VEGF [30, 31]. Stimulation of VEGF and MMP expressions dramatically elevated tumor angiogenesis and growth [32]. On the other hand, the decrease of MMP-3 expressions may be attributed to reduced VEGF activities. MWNT and PA-MWNT therefore can be a promising and effective way to inhibit VEGF/FGF-2 to prevent tumor growth and invasion.

MMP-3 indirectly controls endothelial cells migration via remodeling of nearby ECM. The decrease of MMP-3 may in part influence blood vessel sprouting. Nevertheless, the morphology of CAM showed no significant difference in branch numbers between MWNT and PA-MWNT treated groups. Furthermore, inhibition of MMP-3 and enhancement of stop formation imply the potential role of PA in anti-angiogenesis. Proteins involved in endothelial cells proliferation or maturation and the relevance between PA and angiogenesis inhibitors such as maspin [33] can be investigated in the future.

In this study, we have found the potential roles of MWNTs and particularly PA-MWNTs in con-

trolling angiogenesis by comparing the morphological changes of blood vessel in CAM from embryo treated with MWNT and PA-MWNT implantation. According to our results, MWNT alone showed anti-angiogenic properties as it decreased the branches as well as increased the stops of blood vessels in CAM. PA appeared to function by assisting the stop formation rather than reducing branches. Moreover PA-MWNT also suppresses MMP-3 expression. Taken together MWNT and PA-MWNT could be a novel and striking anti-angiogenic method to prevent tumor invasion. Considering the potential role of PA in inhibiting endothelial cells growth and proliferation, further study is warranted to investigate their correlation.

Acknowledgements

This study was supported by the National Natural Science Foundation of China (Grant No. 81201897; 81201912), the Program of Fudan University improving young teacher's research ability (Grant No. 20520133503). The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.

Disclosure of conflict of interest

None.

Address correspondence to: Dr. Ding-Fang Cai, Department of Integrative Medicine, Zhongshan Hospital, Fudan University, Shanghai 200032, China. Tel: +86-13701645937; E-mail: dfcai123@163.com

References

- [1] Adams RH and Alitalo K. Molecular regulation of angiogenesis and lymphangiogenesis. *Nat Rev Mol Cell Biol* 2007; 8: 464-478.
- [2] Kurz H, Burri PH and Djonov VG. Angiogenesis and vascular remodeling by intussusception: from form to function. *News Physiol Sci* 2003; 18: 65-70.
- [3] Ambler CA, Schmunk GM and Bautch VL. Stem cell-derived endothelial cells/progenitors migrate and pattern in the embryo using the VEGF signaling pathway. *Dev Biol* 2003; 257: 205-219.
- [4] Dorrell MI and Friedlander M. Mechanisms of endothelial cell guidance and vascular patterning in the developing mouse retina. *Prog Retin Eye Res* 2006; 25: 277-295.
- [5] Ferrara N, Gerber HP and LeCouter J. The biology of VEGF and its receptors. *Nat Med* 2003; 9: 669-676.
- [6] Shibuya M. Differential roles of vascular endothelial growth factor receptor-1 and receptor-2 in angiogenesis. *J Biochem Mol Biol* 2006; 39: 469-478.
- [7] Dudley AC. Tumor endothelial cells. *Cold Spring Harb Perspect Med* 2012; 2: a006536.
- [8] Magnusson PU, Dimberg A, Mellberg S, Lukinius A and Claesson-Welsh L. FGFR-1 regulates angiogenesis through cytokines interleukin-4 and pleiotrophin. *Blood* 2007; 110: 4214-4222.
- [9] Folkman J. What is the evidence that tumors are angiogenesis dependent? *J Natl Cancer Inst* 1990; 82: 4-7.
- [10] Iliina O and Friedl P. Mechanisms of collective cell migration at a glance. *J Cell Sci* 2009; 122: 3203-3208.
- [11] Kurahara S, Shinohara M, Ikebe T, Nakamura S, Beppu M, Hiraki A, Takeuchi H and Shirasuna K. Expression of MMPs, MT-MMP, and TIMPs in squamous cell carcinoma of the oral cavity: Correlations with tumor invasion and metastasis. *Head Neck* 1999; 21: 627-38.
- [12] Sato H and Seiki M. Membrane-type matrix metalloproteinases (MT-MMPs) in tumor metastasis. *J Biochem* 1996; 119: 209-215.
- [13] Ramos-DeSimone N, Hahn-Dantona E, Siple J, Nagase H, French DL and Quigley JP. Activation of matrix metalloproteinase-9 (MMP-9) via a converging plasmin/stromelysin-1 cascade enhances tumor cell invasion. *J Biol Chem* 1999; 274: 13066-13076.
- [14] Tripathi CKM, Banga J and Mishra V. Microbial heparin/heparan sulphate lyases: potential and applications. *Appl Microbiol Biotechnol* 2012; 94: 307-321.
- [15] Azad N, Posadas E, Kwitkowski V, Annunziata C, Barrett T, Premkumar A, Kotz H, Sarosy G, Minasian L and Kohn E. Increased efficacy and toxicity with combination anti-VEGF therapy using sorafenib and bevacizumab. *J Clin Oncol* 2006; 24: 3004.
- [16] Wierzbicki M, Sawosz E, Grodzik M, Prasek M, Jaworski S and Chwalibog A. Comparison of anti-angiogenic properties of pristine carbon nanoparticles. *Nanoscale Res Lett* 2013; 8: 195.
- [17] Portney NG and Ozkan M. Nano-oncology: drug delivery, imaging, and sensing. *Anal Bioanal Chem* 2006; 384: 620-630.
- [18] Murugesan S, Mousa SA, O'connor LJ, Lincoln DW and Linhardt RJ. Carbon inhibits vascular endothelial growth factor- and fibroblast growth factor-promoted angiogenesis. *FEBS Lett* 2007; 581: 1157-1160.
- [19] Cao Y, Linden P, Farnebo J, Cao R, Eriksson A, Kumar V, Qi JH, Claesson-Welsh L and Alitalo K. Vascular endothelial growth factor C induces angiogenesis in vivo. *Proc Natl Acad Sci U S A* 1998; 95: 14389-14394.
- [20] Plate KH, Breier G, Weich HA and Risau W. Vascular endothelial growth factor is a potential

- tumour angiogenesis factor in human gliomas in vivo. *Nature* 1992; 359: 845-8.
- [21] Leung DW, Cachianes G, Kuang WJ, Goeddel DV and Ferrara N. Vascular endothelial growth factor is a secreted angiogenic mitogen. *Science* 1989; 246: 1306-1309.
- [22] Hicklin DJ and Ellis LM. Role of the vascular endothelial growth factor pathway in tumor growth and angiogenesis. *J Clin Oncol* 2005; 23: 1011-1027.
- [23] Breier G, Albrecht U, Sterrer S and Risau W. Expression of vascular endothelial growth factor during embryonic angiogenesis and endothelial cell differentiation. *Development* 1992; 114: 521-532.
- [24] Nelson AR, Fingleton B, Rothenberg ML and Matrisian LM. Matrix metalloproteinases: biologic activity and clinical implications. *J Clin Oncol* 2000; 18: 1135-1135.
- [25] Heppner KJ, Matrisian LM, Jensen RA and Rodgers WH. Expression of most matrix metalloproteinase family members in breast cancer represents a tumor-induced host response. *Am J Pathol* 1996; 149: 273.
- [26] Mercurio J, Lopez De Cicco R, Castresana JS and Klein-Szanto AJ. Stromelysin-1/matrix metalloproteinase-3 (MMP-3) expression accounts for invasive properties of human astrocytoma cell lines. *Int J Cancer* 2003; 106: 676-682.
- [27] Fenrick R, Wang L, Nip J, Amann JM, Rooney RJ, Walker-Daniels J, Crawford HC, Hulboy DL, Kinch MS and Matrisian LM. TEL, a putative tumor suppressor, modulates cell growth and cell morphology of ras-transformed cells while repressing the transcription of stromelysin-1. *Mol Cell Biol* 2000; 20: 5828-5839.
- [28] Monvoisin A, Bisson C, Si-Tayeb K, Balabaud C, Desmoulière A and Rosenbaum J. Involvement of matrix metalloproteinase type-3 in hepatocyte growth factor-induced invasion of human hepatocellular carcinoma cells. *Int J Cancer* 2002; 97: 157-162.
- [29] Shima I, Sasaguri Y, Kusakawa J, Yamana H, Fujita H, Kakegawa T and Morimatsu M. Production of matrix metalloproteinase-2 and metalloproteinase-3 related to malignant behavior of esophageal carcinoma. A clinicopathologic study. *Cancer* 1992; 70: 2747-2753.
- [30] Wang H and Keiser JA. Vascular endothelial growth factor upregulates the expression of matrix metalloproteinases in vascular smooth muscle Cells role of Flt-1. *Circ Res* 1998; 83: 832-840.
- [31] Hashimoto G, Inoki I, Fujii Y, Aoki T, Ikeda E and Okada Y. Matrix metalloproteinases cleave connective tissue growth factor and reactivate angiogenic activity of vascular endothelial growth factor 165. *J Biol Chem* 2002; 277: 36288-36295.
- [32] Tang Y, Nakada MT, Kesavan P, McCabe F, Millar H, Rafferty P, Bugelski P and Yan L. Extracellular matrix metalloproteinase inducer stimulates tumor angiogenesis by elevating vascular endothelial cell growth factor and matrix metalloproteinases. *Cancer Res* 2005; 65: 3193-3199.
- [33] Zhang M, Volpert O, Shi YH and Bouck N. Maspin is an angiogenesis inhibitor. *Nat Med* 2000; 6: 196-199.